Patients deserve the BEST
Patients deserve the best
CIRCULOGENE uses an innovative approach that has helped oncologists personalize and monitor treatment plans for over 25,000 cancer patients, with the goal of better outcomes and survival. CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.
Each patient’s cancer is unique, understanding the origins and severity of the cancers aids oncologists to personalize the patient’s treatment plan at the time of diagnosis and throughout their cancer journey.
The CIRCULOGENE Best-in-Class Advantage
CIRCULOGENE begins some tests with a proprietary enrichment process resulting to increase the yield of cfDNA and preserve fragile cfRNA yields. By eliminating the need for a purification step, CIRCULOGENE overcomes the limitations associated with sample volume requirements. This process preserves and extracts fragile cfRNA, enabling fusions and plasma PD-L1 to be effectively detected.

Combined Methodologies

CIRCULOGENE News
Circulogene Announces Exclusive Commercial Launch of LungLifeAI® for Indeterminate Pulmonary Nodule Assessment
Circulogene is excited to announce the exclusive commercial launch of LungLifeAI®, a breakthrough AI-driven blood-based…
Six Molecular Diagnostic Companies To Watch- CIRCULOGENE featured on Labiotech.eu
Labiotech.eu was founded in 2014 by two biotech engineers in response to the lack of…